AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Branched-chain-amino-acid aminotransferase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O15382

UPID:

BCAT2_HUMAN

Alternative names:

Placental protein 18

Alternative UPACC:

O15382; B2RB87; O00269; Q96KG1; Q9BTB6; Q9BUU6

Background:

Branched-chain-amino-acid aminotransferase, mitochondrial, also known as Placental protein 18, plays a pivotal role in the metabolism of essential branched chain amino acids leucine, isoleucine, and valine. Its ability to catalyze the first reaction in their catabolism and potentially function as a transporter highlights its multifaceted role in biological systems.

Therapeutic significance:

The protein's link to Hypervalinemia and hyperleucine-isoleucinemia, a metabolic disorder characterized by elevated plasma concentrations of valine and leucine/isoleucine, underscores its therapeutic significance. The discovery of variants reducing the enzyme's activity and the positive response to vitamin B6 treatment illuminate pathways for targeted therapies, enhancing our understanding of metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.